首页> 外文期刊>Clinical and experimental rheumatology >Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis
【24h】

Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis

机译:FIN-RACo试验的长期结果;结合传统的可缓解疾病的抗风湿药进行治疗是早期类风湿关节炎的绝佳选择

获取原文
获取原文并翻译 | 示例
           

摘要

The Finnish Rheumatoid Arthritis Combination Therapy Trial (FIN-RACo) started in 1993, in an era of disappointing results in the treatment of rheumatoid arthritis (RA). The FIN-RACo was the first trial aiming at remission and comparing two different treatment strategies: initially triple therapy with compulsory prednisolone (FIN-RACo strategy), or monotherapy with optional prednisolone (SINGLE strategy). The results at 2, 5 and at 11 years are in favour of the initial FIN-RACo strategy without an increase in adversities. Nevertheless, with targeted treatment, even the SINGLE strategy group patients show low disease activity and moderate radiographic progression.
机译:芬兰类风湿关节炎联合疗法试验(FIN-RACo)始于1993年,当时风湿关节炎(RA)的治疗效果令人失望。 FIN-RACo是针对缓解和比较两种不同治疗策略的第一项试验:最初采用强制性泼尼松龙的三联疗法(FIN-RACo策略),或采用选择性泼尼松龙的单药治疗(SINGLE策略)。在第2年,第5年和第11年的结果均支持最初的FIN-RACo策略,而没有增加逆境。然而,通过靶向治疗,即使是单策略组患者也显示出较低的疾病活动性和适度的影像学进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号